Victory Pharma, Inc. announced today
the U.S. Food and Drug Administration (FDA) completed its review for the
company's Investigational New Drug (IND) application to evaluate MGX-006, a
unique formulation of a currently marketed agent with indications for
various nausea and vomiting conditions. The MGX-006 program is being
supported via a co-development agreement between Victory and its technology
partner signed in August of 2006. Upon regulatory approval, Victory intends
to market the product through its proprietary U.S. based sales
organization.
"MGX-006 emerged from our strategy to develop and acquire products
utilized for the treatment of pain or pain-related illness," said Dave
Gonyer, Vice President of Commercial Development for Victory Pharma. "Many
patients who experience pain also experience nausea due to the disease
state itself or the treatments for it. We believe that MGX-006 could
provide a significant improvement to the treatment of nausea and vomiting
and substantially improve compliance to benefit patients."
The successful initiation of a second development program represents an
important milestone in Victory's evolution into a leading pain and related
specialty pharmaceutical company. The anti-nausea market remains an area of
unmet medical need with expanding market potential. Many anti-emetics are
used concomitantly with pain products, and are often prescribed by
Victory's target audiences for its current product portfolio. MGX-006 is
targeted to enter pivotal trials in 2007 in conjunction with a leading
clinical research organization.
About Victory Pharmaceuticals
Victory Pharma, Inc. is a private San Diego based specialty
pharmaceutical company focused on acquiring, marketing and developing
proprietary late stage pain and related products. Victory markets its
existing pain products through its physician-based field sales force
deployed throughout the U.S. The Company is developing several products in
pain and pain complementary markets including MGX-001, for treatment of
chronic severe pain and a commonly associated opiate-induced side effect.
MGX-001 is currently in Phase II clinical testing in the United States.
Further information regarding Victory is available at
VictoryPharma.
Victory Pharma, Inc.
VictoryPharma